Micronuclei as intermediate end points in intervention.
Rosin
M P
MP
Division of Epidemiology, Biometry & Occupational Oncology, British Columbia Cancer Agency, Vancouver, Canada.
D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001114:Areca; D002273:Carcinogens; D002869:Chromosome Aberrations; D002986:Clinical Trials as Topic / Q000379:methods; D004534:Egypt / Q000453:epidemiology; D004848:Epithelium / Q000187:drug effects / Q000473:pathology*; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D007249:Inflammation; D015162:Micronucleus Tests; D009062:Mouth Neoplasms / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D017382:Reactive Oxygen Species / Q000494:pharmacology; D012307:Risk Factors; D012553:Schistosomiasis haematobia / Q000150:complications / Q000453:epidemiology; D014030:Tobacco, Smokeless / Q000009:adverse effects; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000209:etiology
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D017382:Reactive Oxygen Species